Alcohol Dependence Clinical Trial
Official title:
The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the
treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and
alcohol dependence.
The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in
reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and
PTSD.
Background:
There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress
disorder (PTSD). The rates of PTSD among individuals with AD are at least twice as high as
those in the general population. In addition, alcohol dependence is the most common comorbid
condition in men with PTSD. Despite this, little is known about how to best treat individuals
with comorbid AD and PTSD. The use of an alpha-1 adrenergic receptor antagonist represents a
novel approach to treatment that may target symptoms of both AD and PTSD. There is evidence
of common neurobiological mechanisms that underlie both AD and PTSD. Prazosin is an alpha-1
adrenergic receptor antagonist that has been used successfully in the treatment of trauma
nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.
Objective:
The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in
reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and
PTSD. Methods: Thirty participants with a current diagnosis of AD and PTSD will be enrolled
in a 13-week trial. They will be assigned, in a double-blind fashion, to either prazosin or
placebo. Significance: This project will be the first to compare prazosin to placebo as
effective treatments for reducing alcohol consumption and PTSD symptoms in patients with both
AD and PTSD.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
| Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
| Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
| Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
| Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
| Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
| Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
| Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
| Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
| Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
| Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
| Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
| Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
| Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
| Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
| Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
| Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
| Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
| Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
| Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |